218 related articles for article (PubMed ID: 32926754)
21. A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia.
Katsuyama H; Yanai H; Adachi H; Hakoshima M
Gastroenterology Res; 2023 Aug; 16(4):240-243. PubMed ID: 37691751
[TBL] [Abstract][Full Text] [Related]
22. Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate.
Sasaki Y; Raza-Iqbal S; Tanaka T; Murakami K; Anai M; Osawa T; Matsumura Y; Sakai J; Kodama T
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766193
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825
[TBL] [Abstract][Full Text] [Related]
24. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
[TBL] [Abstract][Full Text] [Related]
25. Real-world Profile of a Selective Peroxisome Proliferator-activated Receptor α Modulator (SPPARMα) in Japanese Patients with Renal Impairment and Dyslipidemia.
Komatsu T; Miura T; Joko K; Sunohara D; Mochidome T; Kasai T; Ikeda U
Intern Med; 2021 Sep; 60(17):2741-2748. PubMed ID: 33776008
[TBL] [Abstract][Full Text] [Related]
26. Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score.
Hatanaka T; Kosone T; Saito N; Takakusagi S; Tojima H; Naganuma A; Takagi H; Uraoka T; Kakizaki S
JGH Open; 2021 Oct; 5(10):1183-1189. PubMed ID: 34622006
[TBL] [Abstract][Full Text] [Related]
27. Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up.
Ikeda S; Sugihara T; Kihara T; Matsuki Y; Nagahara T; Takata T; Kitao S; Okura T; Yamamoto K; Isomoto H
Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943553
[TBL] [Abstract][Full Text] [Related]
28. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
Iitake C; Masuda D; Koseki M; Yamashita S
Cardiovasc Diabetol; 2020 Nov; 19(1):201. PubMed ID: 33246467
[TBL] [Abstract][Full Text] [Related]
29. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
Honda Y; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Fujita K; Yoneda M; Takizawa T; Saito S; Nagashima Y; Nakajima A
Sci Rep; 2017 Feb; 7():42477. PubMed ID: 28195199
[TBL] [Abstract][Full Text] [Related]
30. Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study.
Ono H; Atsukawa M; Tsubota A; Arai T; Suzuki K; Higashi T; Kitamura M; Shioda-Koyano K; Kawano T; Yoshida Y; Okubo T; Hayama K; Itokawa N; Kondo C; Nagao M; Iwabu M; Iwakiri K
JGH Open; 2024 Apr; 8(4):e13057. PubMed ID: 38572327
[TBL] [Abstract][Full Text] [Related]
31. Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.
Matsuba I; Matsuba R; Ishibashi S; Yamashita S; Arai H; Yokote K; Suganami H; Araki E
J Diabetes Investig; 2018 Nov; 9(6):1323-1332. PubMed ID: 29603684
[TBL] [Abstract][Full Text] [Related]
32. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
Tanaka A; Nakamura T; Sato E; Chihara A; Node K
CEN Case Rep; 2020 May; 9(2):141-146. PubMed ID: 31950425
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease.
Tamai H; Okamura J
Hepatol Res; 2023 Mar; 53(3):258-266. PubMed ID: 36378065
[TBL] [Abstract][Full Text] [Related]
34. Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury.
Konishi H; Miyauchi K; Onishi A; Suzuki S; Fuchimoto D; Shitara J; Endo H; Wada H; Doi S; Naito R; Ogita M; Dohi T; Kasai T; Daida H
PLoS One; 2020; 15(11):e0241195. PubMed ID: 33201888
[TBL] [Abstract][Full Text] [Related]
35. Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials.
Guo XF; Yang B; Tang J; Li D
Clin Nutr; 2018 Feb; 37(1):113-122. PubMed ID: 28161092
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of pemafibrate in patients with hypertriglyceridemia in clinical settings: A retrospective study.
Katakura Y; Shimoda M; Ohnishi M; Kusano T; Dan K; Isobe H; Wamata R; Iwamoto Y; Fushimi Y; Sanada J; Obata A; Kimura T; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
Nutr Metab Cardiovasc Dis; 2023 Jul; 33(7):1444-1452. PubMed ID: 37246074
[TBL] [Abstract][Full Text] [Related]
37. [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
Ren SM; Mei L; Huang H; Cao SF; Zhao RH; Zheng PY
Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):369-375. PubMed ID: 31177662
[No Abstract] [Full Text] [Related]
38. Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes.
Hoshino T; Ishizuka K; Toi S; Seki M; Kitagawa K
J Atheroscler Thromb; 2022 Jul; 29(7):1020-1030. PubMed ID: 34248089
[TBL] [Abstract][Full Text] [Related]
39. Effects of the ratio of polyunsaturated and monounsaturated fatty acid to saturated fatty acid on rat plasma and liver lipid concentrations.
Chang NW; Huang PC
Lipids; 1998 May; 33(5):481-7. PubMed ID: 9625595
[TBL] [Abstract][Full Text] [Related]
40. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
